Mirum Expands LIVMARLI Formulation Options in Canada with Tablet Authorization
Event summary
- Health Canada authorized LIVMARLI® tablet formulation for Alagille syndrome (ALGS) patients weighing 22 kg or more.
- Tablet complements existing oral solution, offering flexible dosing for older ALGS patients.
- LIVMARLI is now authorized in Canada for both ALGS and progressive familial intrahepatic cholestasis (PFIC).
- Mirum aims to improve treatment adherence and continuity of care as patients age.
The big picture
Mirum’s expansion of LIVMARLI’s formulation options in Canada aligns with its strategy to address unmet needs in rare liver diseases. The move reflects a broader industry trend of developing flexible dosing solutions to improve patient compliance and outcomes. With ALGS affecting approximately 1 in 30,000 people, Mirum’s ability to cater to different age groups could enhance its market position in the rare disease space.
What we're watching
- Market Penetration
- Whether the tablet formulation will drive higher adoption among older ALGS patients.
- Regulatory Strategy
- The pace at which Mirum secures similar approvals in other markets.
- Pipeline Progress
- How this approval impacts the broader development of LIVMARLI for other indications.
Related topics